Materiały źródłowe

• #1 SciELO Brazil – Bullous pemphigoid Bullous pemphigoid

  https://www.scielo.br/j/abd/a/BsschZpGNWjSKJ3rFKBCXjm/

  Bullous pemphigoid is the most frequent autoimmune blistering disorder. It affects mainly elderly individuals, during the 8th decade of life, without gender predilection, with rare case reports of BP in children and adolescents. The incidence of BP has increased over the past decades as a result of population aging with multiple comorbidities and exposure to drugs that may potentially trigger the disease, as well as improvement in the clinical diagnosis of non-bullous presentations and in the accuracy of laboratory techniques to demonstrate the presence of autoantibodies against hemidesmosomal proteins. Epidemiological studies of BP in Europe demonstrate the incidence ranges from 2.5 to 42.8 cases/million/year, whereas in Asia the annual incidence is estimated in 2.6 to 7.5 cases/million. Statistical differences may be related to the type of study performed (retrospective vs. prospective), duration and collected data (national databases, chart review). The frequency of BP also increases in patients older than 80 years, with nearly 150-330 new cases/million/year at this age range.

• #2 Bullous pemphigoid* | Anais Brasileiros de Dermatologia (Portuguese)

  https://www.anaisdedermatologia.org.br/pt-bullous-pemphigoid-articulo-S0365059620305778

  Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects elderly individuals. […] The incidence of BP has increased over the past decades as a result of population aging with multiple comorbidities and exposure to drugs that may potentially trigger the disease, as well as improvement in the clinical diagnosis of non-bullous presentations and in the accuracy of laboratory techniques to demonstrate the presence of autoantibodies against hemidesmosomal proteins. […] Epidemiological studies of BP in Europe demonstrate the incidence ranges from 2.5 to 42.8 cases/million/year, whereas in Asia the annual incidence is estimated in 2.6 to 7.5 cases/million. […] The frequency of BP also increases in patients older than 80 years, with nearly 150-330 new cases/million/year at this age range.

• #3 Bullous Pemphigoid – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK535374/

  Bullous pemphigoid affects individuals older than 60. Annual incidence is 6 to 13 new cases per million people in the United States, while it affects 12 to 13 per million in Central Europe. It has an equal incidence in males and females and no racial bias. […] Specific HLA class II alleles can be found in bullous pemphigoid patients, including the allele DQB1*0301 in White race patients and alleles DRB1*04, DRB1*1101, and DQB1*0302 in Japanese patients.

• #4 The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6109638/

  Bullous pemphigoid (BP) is the most common type of subepidermal autoimmune bullous diseases. BP characteristically affects the elderly and is seen mainly in patients older than 70 years. While the annual incidence of BP has been estimated to be between 2.4 and 23 cases per million in the general population, it rises exponentially to 190312 cases per million in individuals older than 80 years. In addition, a growing body of evidence reports a remarkable trend of increased incidence of BP, showing a 1.9- to 4.3-fold rise over the past two decades. This demonstrable increase warrants a higher awareness of the increased risk to develop BP. This review summarizes the current understanding of the epidemiological features of BP and sheds light on the putative explanations for its growing incidence.

• #5 Bullous Pemphigoid: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/1062391-overview

  Bullous pemphigoid is uncommon, and its precise frequency has not been definitively established. […] In Europe, bullous pemphigoid has been identified as the most common subepidermal autoimmune blistering disease. In France and Germany, the reported incidence is 6.6 cases per million people per year. In a population-based cohort study from the United Kingdom, the incidence of bullous pemphigoid was found to be 4.3 cases per 100,000 person-years. […] Bullous pemphigoid primarily affects elderly individuals in the fifth through seventh decades of life (average age at onset, 65 y). Bullous pemphigoid of childhood onset has been reported in the literature. It has been suggested that the childhood-onset form may be more self-limited. […] The incidence of bullous pemphigoid appears to be equal in men and women. […] No racial predilection is apparent.

• #6 Clinical review: Bullous pemphigoid | GPonline

  https://www.gponline.com/clinical-review-bullous-pemphigoid/dermatology/article/1072223

  Whenever tense bullae are present, bullous pemphigoid (BP), which is the most common autoimmune blistering condition in the developed world and one of the immunobullous disorders, must come to mind. […] The incidence has been underestimated in the past, but a recent study found it to be 4.3 (95% CI 4.0-4.6) per 100,000 person-years in the UK. […] It is likely that this figure still underestimates the true incidence, especially of those with milder forms of the condition. […] BP is a disease primarily affecting those over 70 years of age, so the incidence is expected to increase in future in countries with ageing populations. […] The mortality in patients with BP is twice that of the general population in the UK.

• #7 The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6109638/

  The annual incidence of BP has been estimated to range between 2.4 and 21.7 new cases per million population in different populations worldwide. An even higher annual incidence of 42.8 cases per million population was reported in the United Kingdom (UK), although this report may be interpreted with caution as it is based on a computerized longitudinal general practice database. Also based on health insurance data, the prevalence of BP has recently been estimated at 259 per million population in Germany, i.e., ~21,000 patients with BP lived in Germany as for 2014. Despite this increase, BP is still considered as an orphan disease, i.e., 5 in 100,000 persons are affected by the disease. […] A growing incidence ranging from 1.9- to 4.3-fold in the past two decades has been reported in recent data from the UK, France, Germany, and Israel.

• #8 The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6109638/

  In a retrospective cohort study, the annual incidence of BP was estimated at 21.7 cases per million population throughout the years 20002005 in three French regions: Haute-Normandie, Limousin, and Champagne-Ardennes. This figure represents more than 3-fold increase relative to the annual incidence previously estimated in three adjacent French regions between the years 19861992: Limousin, Touraine, and Picardie, with very similar demographic characteristics (6.7 cases per million population). […] A consistent rise of the annual incidence rates of BP has been reported in the UK during the last two decades; from a nadir of 10.0 cases per million population in 1985, to 14.0 cases per million population during 19912001, and up to 42.8 cases per million population during the 20012004. […] A recent population-based study investigating the epidemiology of BP in Northern Israel revealed a 1.9-fold increasing annual incidence: from 7.6 to 14.3 cases per million population in the calendar periods 20002005 and 20112015, respectively. This rise applied to both of the major ethnic populations residing in the region: Jews and Arabs.

• #9

  https://link.springer.com/article/10.1007/s00403-017-1778-4

  The incidence of BP in Sweden remains sparse, as very few reliable studies have assessed the overall age- and gender-specific distribution of BPs incidence. […] From this large population-based cohort study, we estimated adjusted annual incidence rates of BP in Sweden to be 7.1/100,000 inhabitants. […] The overall incidence increased with age and reached its maximum between the ages of 90 and 99 years (81.9/100,000). […] The adjusted incidence rate of BP is 7.1/100,000 (95% CI 6.5-7.7). […] This is the first nationwide population-based registry study to present valid and robust data on the incidence of BP in an entire country. In total 3761 BP cases were included and the adjusted incidence rate was estimated to 7.1/100,000. This is the highest incidence level in Europe, thus confirming BP as a relatively common disease in the elderly population.

• #10 Bullous Pemphigoid: Clinical Practice Guidelines | Actas Dermo-Sifiliográficas

  https://actasdermo.org/en-bullous-pemphigoid-clinical-practice-guidelines-articulo-S1578219014000778

  Bullous pemphigoid (BP) is the most common blistering disease in the adult population in developed countries, with an estimated incidence in Spain of 0.2 to 3 cases per 100,000 inhabitants per year. […] While recently published studies have pointed to an increase in recent years, a French study published in just 2012 reported an incidence of 21.7 cases per million inhabitants a year. […] The disease affects a similar proportion of men and women. Most patients are over 75 years old, but young adults and even children can also develop BP. […] Several cases reporting an association between BP and different malignant diseases have been published, but in one case-control study with matching for age and sex no increased risk for malignancy was observed in BP patients.

• #11 Orphanet: Bullous pemphigoid

  https://www.orpha.net/en/disease/detail/703

  Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. It has an estimated prevalence of 1/4,000 in Europe. The incidence is reported to be increasing but currently ranges between 2-22/1,000,000 worldwide. […] BP predominantly affects the elderly with an average age of 80 years and is significantly associated with neurological disorders. Some cases have also been described in children and young adults.

• #12

  https://www.nottingham.ac.uk/research/groups/cebd/projects/blistering-diseases/epidemiology-of-bullous-pemphigoid.aspx

  We aimed to improve our understanding of the people affected by bullous pemphigoid in England 1998-2017. Bullous pemphigoid most commonly affects older people, particularly older men. Over the last two decades, we found that slightly more people are being diagnosed with bullous pemphigoid each year. Those with bullous pemphigoid were more likely to die early than those without the disease. […] Understanding who is affected, how many are affected, and the consequences of bullous pemphigoid is important, but hasnt been looked at in the UK in over a decade. […] Every year, about 8 people in every 100,000 are diagnosed with bullous pemphigoid for the first time. This number has been rising slowly over the last two decades. Bullous pemphigoid more commonly affects older people, particularly older men. In 2017, about 50 in every 100,000 adults were living with bullous pemphigoid. Focusing only on older people (60 years), just over 1 in every 1,000 older person was living with bullous pemphigoid in 2017. People with bullous pemphigoid were more likely to die than similar people without the disease three times more likely in the first two years after being diagnosed, and then 50% more likely following this.

• #13 Bullous Pemphigoid Epidemiology Forecast Report 2018-2020 & 2021-2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210415005567/en/Bullous-Pemphigoid-Epidemiology-Forecast-Report-2018-2020-2021-2030—ResearchAndMarkets.com

  The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Bullous Pemphigoid, Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid, Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid, and Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030. […] In 2020, the total diagnosed prevalent cases of bullous pemphigoid in the 7MM were 124,517 which is likely to increase by 2030 at a CAGR of 0.96% for the study period (2018-2030). […] In 2020, there were 25,041 diagnosed prevalent cases of bullous pemphigoid in the United States, these cases are expected to increase at a CAGR of 1.26% for the study period of 2018-2030.

• #14 Bullous Pemphigoid Market is Expected to Grow With a CAGR of 16.27% for the Study Period of 2018-2030, says DelveInsight

  https://www.prnewswire.com/news-releases/bullous-pemphigoid-market-is-expected-to-grow-with-a-cagr-of-16-27-for-the-study-period-of-20182030–says-delveinsight-301247051.html

  Bullous Pemphigoid treatment market to derive enormous growth from rising geriatric population along with expected launch of emerging therapies in forecasted period (2021-2030) […] DelveInsight’s „Bullous Pemphigoid Market” report provides a thorough comprehension of the Bullous Pemphigoid, historical and forecasted epidemiology, and the Bullous Pemphigoid market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. […] According to DelveInsight’s analysts, the total diagnosed Bullous Pemphigoid prevalent cases was 124,517 in the 7MM in 2020. […] The Bullous Pemphigoid Market Report provides historical as well as forecasted epidemiological analysis segmented into: Diagnosed Prevalent cases, Gender-specific Diagnosed Prevalent Cases, Age-specific Diagnosed Prevalent Cases, Severity-specific Diagnosed Prevalent Cases.

• #15 Epidemiology and Comorbidities of Bullous Pemphigoid: A Retrospective Study – Journal of the Turkish Academy of Dermatology

  https://jtad.org/articles/epidemiology-and-comorbidities-of-bullous-pemphigoid-a-retrospective-study/doi/jtad.galenos.2020.68552

  Bullous pemphigoid is the most common autoimmune subepidermal bullous dermatosis which is most commonly seen in the elderly population. […] The aim of this study is to determine the female-to-male ratio and the mean ages of diagnoses; disease durations and comorbidities separately in the female and male Turkish patient groups. […] For the 58 patients included in this study the female-to-male ratio was 1.42. The average age of diagnosis was 73.79 years (15-103 years). […] Bullous pemphigoid has a female predominance and is usually diagnosed during the seventh decade. […] This study showed an association between bullous pemphigoid and cardiac diseases or diabetes mellitus. […] Bullous pemphigoid is a disease of the elderly and it was previously reported that the prevalence of bullous pemphigoid in the 9th decade is 300-fold that of the 6th decade.

• #16 Bullous pemphigoid: An immune disorder related to aging (Review)

  https://www.spandidos-publications.com/10.3892/etm.2021.10972

  Bullous pemphigoid (BP) is the most frequent subepidermal autoimmune blistering disease and is caused by autoantibodies directed against two principal antigens of the hemidesmosome, BP antigen 180 and BP antigen 230. […] The epidemiology of BP clearly shows that this is a disease of the elderly. Its triggers and comorbidities have been reviewed thus far, highlighting their association with advanced age. […] BP is the most frequent autoimmune blistering disorder, with a reported prevalence of 250 patients/million individuals and an incidence rate of 43 cases/million annually for the general population in the United Kingdom. […] Furthermore, the incidence rate of BP increases exponentially with age, reaching ~190-312 cases/million each year when considering only individuals over the age of 80.

• #17 Bullous pemphigoid: An immune disorder related to aging (Review)

  https://www.spandidos-publications.com/10.3892/etm.2021.10972

  A 300-fold risk increase in developing BP has been estimated in patients aged over 90 compared to individuals of 60 years or younger. […] The pathology of BP results from the complex interaction of multiple mechanisms, including genetic predisposition, skin barrier changes, immunosenescence and triggering factors. The epidemiology of BP displays a predilection for elderly individuals. […] In conclusion, restoring skin barrier integrity should be a treatment goal for all patients with BP. This strategy could prove particularly beneficial in elderly individuals, in whom frequent comorbidities associated with age often limit the availability of treatment options.

• #18 Bullous Pemphigoid: Causes, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/15855-bullous-pemphigoid

  Bullous pemphigoid most commonly affects people over 60 years old, but it may also appear in younger people, too. Its more common in the Western world, and uncommon in the Far East. […] Bullous pemphigoid is relatively rare. There are between 2.4 and 23 cases per 1 million people in the general population. However, in people 80 years of age and older, there are between 190 and 312 cases per 1 million. […] Healthcare providers and medical researchers arent sure how to prevent bullous pemphigoid.

• #19 Bullous Pemphigoid Epidemiology Forecast Report 2018-2020 & 2021-2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210415005567/en/Bullous-Pemphigoid-Epidemiology-Forecast-Report-2018-2020-2021-2030—ResearchAndMarkets.com

  Assessments as per this analysis showed that there were 13,772 cases of the mild-moderate form of bullous pemphigoid and 11,268 cases of the severe form of bullous pemphigoid in the United States in 2020. […] Assessments as per the analysts showed that 47% of total cases of bullous pemphigoid in the United States in 2020 were from the age group above 80 years. […] In 2020, males and females contributed to 44% and 56% of the total diagnosed prevalent cases of Bullous Pemphigoid in the United States, respectively. […] Among the European countries, the UK had the highest diagnosed prevalent population of bullous pemphigoid with 24,644 cases, followed by France which had 23,843 diagnosed prevalent cases in 2020. On the other hand, Spain had the lowest diagnosed prevalent population of 10,920 in 2020. […] In 2020, Japan accounted for 8,619 diagnosed prevalent cases of bullous pemphigoid which is the least cases among 7MM countries.

• #20 Global Bullous Pemphigoid Market to 2025 – Insights, Epidemiology and Forecasts – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210510005427/en/Global-Bullous-Pemphigoid-Market-to-2025—Insights-Epidemiology-and-Forecasts—ResearchAndMarkets.com

  In 2020, there were 25,041 diagnosed prevalent cases of bullous pemphigoid in the United States, these cases are expected to increase at a CAGR of 1.26% for the study period of 2018-2030. […] Assessments as per this analysis showed that there were 13,772 cases of the mild-moderate form of bullous pemphigoid and 11,268 cases of the severe form of bullous pemphigoid in the United States in 2020. […] Assessments as per the analysts showed that 47% of total cases of bullous pemphigoid in the United States in 2020 were from the age group above 80 years. […] In 2020, males and females contributed to 44% and 56% of the total diagnosed prevalent cases of Bullous Pemphigoid in the United States, respectively. […] Among the European countries, the UK had the highest diagnosed prevalent population of bullous pemphigoid with 24,644 cases, followed by France which had 23,843 diagnosed prevalent cases in 2020. On the other hand, Spain had the lowest diagnosed prevalent population of 10,920 in 2020. […] In 2020, Japan accounted for 8,619 diagnosed prevalent cases of bullous pemphigoid which is the least cases among 7MM countries.

• #21 Epidemiology and Comorbidities of Bullous Pemphigoid: A Retrospective Study – Journal of the Turkish Academy of Dermatology

  https://jtad.org/articles/epidemiology-and-comorbidities-of-bullous-pemphigoid-a-retrospective-study/doi/jtad.galenos.2020.68552

  The average age of diagnosis was found to be 73.79 years for both genders. […] The most commonly observed comorbidities in bullous pemphigoid patients were hypertension in 26 patients (45%), diabetes mellitus in 14 patients (24%), coronary artery diseases in 6 patients (1%), chronic kidney disease in 4 patients (0.7%) and osteoporosis in 4 patients (0.7%). […] Cardiovascular diseases, including hypertension and coronary artery diseases, were reported to co-exist with bullous pemphigoid ranging from 38% up to 70% in several previous studies. […] Bullous pemphigoid is an autoimmune blistering disease with a female predominance which is usually diagnosed during the seventh decade; according to the previous literature and this study. […] Previous studies have shown that bullous pemphigoid was associated with cardiac diseases, diabetes mellitus, neurologic and psychiatric diseases. […] However, the results failed to show an association with neurologic or psychiatric diseases. […] Bullous pemphigoid was reported to be not associated with malignancies; similarly, this study did not find a significant prevalence of history of malignant neoplasms in bullous pemphigoid patients.

• #22 Risk of Death in Bullous Pemphigoid: A Retrospective Database Study in Finland | HTML | Acta Dermato-Venereologica

  https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2347

  The most common comorbidities were cardiovascular diseases (76.3%) and neurodegenerative diseases (40.9%). […] Of these comorbidities, only malignancy predicted significantly increased 1-year mortality, the age- and sex-adjusted hazard ratio (HR) being 2.4. […] Concomitant medications used for other diseases were very common in patients with BP; the number of regularly used drugs ranging from 0 to 19. […] Interestingly, polypharmacy had a significant association with mortality: the higher the number of drugs, the greater the 1-year and 2-year mortality. […] This study found that the SMR mortality for immunologically confirmed BP was 7.6-fold that of an age-matched reference population and the 1- and 2-year mortalities were 16.7% and 30.3%, respectively. […] In general, polypharmacy in elderly patients has been shown to be an independent marker of increased mortality.

• #23 SciELO Brazil – Bullous pemphigoid Bullous pemphigoid

  https://www.scielo.br/j/abd/a/BsschZpGNWjSKJ3rFKBCXjm/

  Both BP and neurological diseases affect elderly individuals with multiple comorbidities under the use of several medications, and epidemiological studies provided evidence that their coexistence is not coincidental. A systematic review with meta-analysis evaluated 14 studies with 23,369 BP patients and 128,697 controls. This review indicates that BP patients are 5 times more prone to develop any neurologic disorder, mainly multiple sclerosis, dementia, Parkinson’s disease, epilepsy and stroke, which usually precedes the onset of BP by 5.5 years. Multiple sclerosis has the highest association, with a 5-12 time risk of development of BP. […] A recent systematic review and meta-analysis included 25 studies and demonstrated a 1-year combined mortality rate of 23.5%. Higher mortality rates were obtained in Europe (26.7%) followed by Asia (20.5%) and US (15.1%), possibly related to an increased number of comorbidities and older age in European patients in comparison to Americans and Asians, respectively.

• #24 Risk of Death in Bullous Pemphigoid: A Retrospective Database Study in Finland | HTML | Acta Dermato-Venereologica

  https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2347

  All studies, including ours, agree that patients with BP have increased mortality compared with the general population of the same age. […] The association between BP and neurological disorders has been established in many studies; the mechanism behind this could be an autoinflammatory reaction to BP180 and/or BP230 neuronal isoforms which are present in the human brain. […] In conclusion, patients with BP have increased mortality compared with the general population.

• #25 Risk of Death in Bullous Pemphigoid: A Retrospective Database Study in Finland | HTML | Acta Dermato-Venereologica

  https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2347

  Bullous pemphigoid (BP) is an autoimmune skin disease of elderly people, which is associated with increased mortality. […] The aim of this study was to investigate the standardized mortality ratio (SMR) for BP in Finland, and concomitant comorbidities and medications. […] In conclusion, the mortality for BP in Finland is 7.6-fold that of a reference population, and malignancies and polypharmacy are associated with increased mortality. […] The incidence of BP is 2.5-42.8 per 1 million person-years, and it has been reported to have increased in the UK, France, USA and Finland. […] BP is associated with significant mortality; 10.8-41% within the first year after diagnosis. […] Patients with BP also have increased mortality compared with their age- and sex-adjusted counterparts in the general population; the standardized mortality ratio ranges from 1.9 to 9.6.

• #26 Bullous Pemphigoid: Causes, Symptoms, and Treatment — DermNet

  https://dermnetnz.org/topics/bullous-pemphigoid

  Bullous pemphigoid often presents in people over 80 years of age, and mostly affects people over 50. […] It is more prevalent in older patients with neurological disease, particularly stroke, dementia and Parkinson disease. […] The risk of developing bullous pemphigoid is greater in people with psoriasis, and it can be precipitated by treatment of psoriasis with phototherapy. […] Bullous pemphigoid can be a serious disease, particularly when widespread or resistant to treatment. […] The Bullous Pemphigoid Disease Area Index (BPDAI) has separate scores for skin and mucous membrane activity. […] It is not known how to prevent bullous pemphigoid. […] Treatment for bullous pemphigoid is usually needed for several years.

• #27 Cicatricial (Mucous Membrane) Pemphigoid: Background, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1062534-overview

  The incidence of mucous membrane pemphigoid (MMP) has been estimated to be 2 cases per million in studies performed in France and Germany. […] Pure ocular mucous membrane pemphigoid occurs in less than 1 case per million in the United Kingdom. […] Among white patients in the United States, mucous membrane pemphigoid is associated with human leukocyte antigen DQB1*0301 (HLA-DQB1*0301). […] Most studies have demonstrated a female-to-male ratio of approximately 2:1. […] Most patients with mucous membrane pemphigoid are elderly, with a mean age of 62-66 years.

• #28

  https://www.nottingham.ac.uk/research/groups/cebd/projects/blistering-diseases/epidemiology-of-bullous-pemphigoid.aspx

  This study has improved our understanding of bullous pemphigoid in England. Importantly, we have shown that bullous pemphigoid is more common in older people than what was previously thought and that it continues to be life-limiting. We hope that increased awareness of the disease and its associated mortality will improve the diagnosis and management of patients in the future.

• #29 Bullous Pemphigoid – Market Insight, Epidemiology and Market Forecast -2032

  https://www.researchandmarkets.com/reports/5292790/bullous-pemphigoid-market-insight?srsltid=AfmBOorSLO__t7mdwC-rAdF__JfFnNPjFrzY7kUu6WEn1kndL_mrIBo2

  This „Bullous Pemphigoid- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Bullous Pemphigoid, historical and forecasted epidemiology as well as the Bullous Pemphigoid market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. […] The Bullous Pemphigoid epidemiology division provide insights about historical and current Bullous Pemphigoid patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken. […] The disease epidemiology covered in the report provides historical as well as forecasted Bullous Pemphigoid epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

• #30 Bullous Pemphigoid – Market Insight, Epidemiology and Market Forecast -2032

  https://www.researchandmarkets.com/reports/5292790/bullous-pemphigoid-market-insight?srsltid=AfmBOorSLO__t7mdwC-rAdF__JfFnNPjFrzY7kUu6WEn1kndL_mrIBo2

  The epidemiology segment also provides the Bullous Pemphigoid epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. […] What is the historical Bullous Pemphigoid patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan? […] What would be the forecasted patient pool of Bullous Pemphigoid in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan? […] Out of all 7MM countries, which country would have the highest prevalent population of Bullous Pemphigoid during the forecast period (2019-2032)?

• #31 Bullous pemphigoid – A blistering problem

  https://www.medsafe.govt.nz/profs/PUArticles/March2019/Bullous%20pemphigoid%20blistering%20problem.htm

  Bullous pemphigoid is an autoimmune blistering skin disease that mainly affects the elderly. […] Most cases of bullous pemphigoid occur in individuals aged over 60 years. […] The risk of bullous pemphigoid is increased with advanced age. […] In New Zealand, between 1965 and 2018, the Centre for Adverse Reactions Monitoring (CARM) received 20 reports of pemphigoid reactions suspected to be caused by a medicine.

• #32 A retrospective cohort study of the epidemiology and clinical management of pemphigus in England | CPRD

  https://www.cprd.com/approved-studies/retrospective-cohort-study-epidemiology-and-clinical-management-pemphigus-england

  There are rare skin conditions called pemphigus and bullous pemphigoid that cause large and widespread blisters. These skin conditions can occur at any age but is most often seen in people when they are middle-aged or older. […] Previous UK studies, including those using data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) data, show a rise in pemphigus and bullous pemphigoid incidence along with high mortality between the late 1990s and mid-2010s. […] Similarly, studies investigating bullous pemphigoid have reported incidences between 0.2 and 4.3 per 100000 person years, with higher incidence (7.6 and 8.4 per 100,000 person-years) being reported in recent years. […] While separate CPRD studies have looked at aspects of the burden and treatment of pemphigus and bullous pemphigoid, we aim to provide a complete summary of the disease epidemiology including incidence, prevalence, and mortality, along with detailed examination of treatment practices including a treatment pathway mapping and healthcare resource use for a consistent patient population using 12 years of CPRD-HES-ONS linked data.

• #33 Top Published Expert Doctors for Bullous Pemphigoid

  https://findexpertmd.com/d/Bullous_Pemphigoid?physician=physician

  535 top medical experts on Bullous Pemphigoid across 38 countries and 30 U.S. states, including 400 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants. […] Clinical Trials: at least 60 including 2 Active, 22 Completed, 14 Recruiting.

• #34 Autoimmune blistering diseases – Knowledge @ AMBOSS

  https://www.amboss.com/us/knowledge/autoimmune-blistering-diseases/

  Bullous pemphigoid is a chronic relapsing-remitting autoimmune blistering disease that primarily affects older adults. […] Peak incidence: 70 years of age. […] Most common bullous autoimmune disease. […] Oral involvement in 10-30% of patients. […] Disease extent can be assessed using the Bullous Pemphigoid Disease Activity Index or daily blister count. […] Long-term remission is possible. […] Relapse occurs in 30% of patients within 12 months of treatment and in 50% of patients after stopping treatment. […] All patients should be managed by a dermatologist. […] Consult a dermatologist for all patients. […] Patients with extensive pemphigus vulgaris typically require hospital admission.

• #35 Bullous Pemphigoid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  https://www.researchandmarkets.com/reports/5969776/bullous-pemphigoid-market-epidemiology?srsltid=AfmBOooNrG4_vuJjAF5GgypHDj9lBLuu37yzDTYcT_ivYOgQwPDioANs

  Epidemiology – Key Insights […] What is the number of prevalent cases (2018-2034) of bullous pemphigoid across the seven major markets? […] What is the size of the bullous pemphigoid patient pool (2018-2023) across the seven major markets? […] What would be the forecasted patient pool (2024-2034) across the seven major markets? […] What are the key factors driving the epidemiological trend of bullous pemphigoid? […] What will be the growth rate of patients across the seven major markets?

• #36 Bullous Pemphigoid Market is Expected to Grow With a CAGR of 16.27% for the Study Period of 2018-2030, says DelveInsight

  https://www.prnewswire.com/news-releases/bullous-pemphigoid-market-is-expected-to-grow-with-a-cagr-of-16-27-for-the-study-period-of-20182030–says-delveinsight-301247051.html

  The rise in the geriatric population and an increase in the risk factors such as neurological disorders, use of certain drugs, and others globally contribute to increased Bullous Pemphigoid prevalence. […] DelveInsight’s Bullous Pemphigoid Epidemiology Forecast 2030 report delivers an understanding of the disease, historical forecasted epidemiology of Bullous Pemphigoid.

• #37 Bullous Pemphigoid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  https://www.researchandmarkets.com/reports/5969776/bullous-pemphigoid-market-epidemiology?srsltid=AfmBOooNrG4_vuJjAF5GgypHDj9lBLuu37yzDTYcT_ivYOgQwPDioANs

  The 7 major bullous pemphigoid markets reached a value of US$ 245.4 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 1,379.3 Million by 2034, exhibiting a growth rate (CAGR) of 21.15% during 2023-2034. […] This report provides an exhaustive analysis of the bullous pemphigoid market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. […] According to the report the United States has the largest patient pool for bullous pemphigoid and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report.

• #38

  https://link.springer.com/article/10.1007/s44197-024-00277-7

  This study aims to conduct an extensive analysis of autoimmune bullous diseases, particularly pemphigus vulgaris and bullous pemphigoid, in Shanghai, China, from 2016 to 2023. […] The global epidemiology of autoimmune bullous disease indicates variability across populations, with some regions reporting higher incidences than others. Studies have demonstrated a greater cumulative incidence of bullous pemphigoid in Europe compared to Asia, while pemphigus, albeit less prevalent, also shows regional variation. Notably, the incidence of pemphigoid has been increasing, particularly in Western countries, over the past two decades. However, comprehensive data on the incidence and prevalence of autoimmune bullous disease in Asia, especially China, are still scarce. […] The mortality rate of 5.5% in autoimmune bullous disease, primarily due to interstitial lung disease, cardiovascular diseases, and pneumonia, is a stark reminder of the severity of these conditions. […] A notable finding is the high prevalence of autoimmune bullous disease among workers in industries requiring occupational protection. This underscores the urgent need for enhanced safety measures and increased awareness in these sectors to mitigate the risk of developing autoimmune bullous disease.

Zobacz więcej